TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00532701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 16 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + LD RBV for 16 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 24 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24
Study: NCT00925093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
Study: NCT01434030

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
Study: NCT01995474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twisted Syringe
Description: briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Technique
Description: syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
Study: NCT03589560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
Study: NCT01901120

Intervention type: DRUG
Intervention: Betanis
Description: oral
Study: NCT06199596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-s1 casein hydrolysate
Description: 150mg of Prelactium per capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 150mg of Maltodextrin per capsule
Study: NCT03868046

Intervention type: DRUG
Intervention: Treatment with immune checkpoint inhibitors.
Description: Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests.
Description: Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
Study: NCT05307146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: macro/micro electrode recording
Description: intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
Study: NCT00532701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 48 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + LD RBV for 24 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved
Study: NCT02274961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-pantoprazole 10mg
Study: NCT02795832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-5212372 1% w/w Ointment BID
Study: NCT00776321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02795832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-5212372 1% w/w Ointment BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-5212372 1% w/w Ointment BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment BID
Study: NCT02202772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravesical installation of Cisplatin for 2hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravesical installation of Cisplatin for 2hours
Study: NCT01219569

Intervention type: DRUG
Intervention: propofol
Description: Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure

Intervention type: DRUG
Intervention: Sevoflurane
Description: sevoflurane 1.5% and 2.5% end tidal in random sequence
Study: NCT00753467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ 1b (Actimmune)
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study: NCT02274961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00648037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
Study: NCT00753467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ 1b and Adefovir dipivoxil combination
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study: NCT03298165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: diode laser
Description: diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
Study: NCT01317030

Intervention type: DEVICE
Intervention: Contact Lens Wear
Description: Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.

Intervention type: DEVICE
Intervention: Contact Lens Wear
Description: Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.

Intervention type: OTHER
Intervention: Non-Contact Lens Wear
Description: No intervention
Study: NCT01699360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A, Tacrolimus, Sirolimus
Study: NCT01482845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
Study: NCT03123770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: a new kind of doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: traditional chemotherapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: traditional chemotherapy drug
Study: NCT01482845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
Study: NCT03123770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: traditional chemotherapy drug used in breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: traditional chemotherapy drug used in breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: traditional chemotherapy drug used in breast cancer
Study: NCT02228161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
Study: NCT02264743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston Conti
Description: Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVOREL® CONTI
Description: Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
Study: NCT01545765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 7% + Tetracaine 7% cream
Description: Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
Study: NCT01294852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surfactant prophylaxis
Description: Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surfactant prophylaxis
Description: Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
Study: NCT03583788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
Study: NCT00267371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFO Closure with Premere investigational device.
Description: PFO Closure with Premere investigational device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management/current medications per standard of care by personal physician.
Description: Medical management with current medications per standard of care by personal physician.
Study: NCT00881790

Intervention type: OTHER
Intervention: Fluoride varnish
Description: the topical application of fluoride varnish to all surfaces of exposed teeth
Study: NCT03491930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA MOVE! Coach app
Description: The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: Weekly Telephone Coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for weight loss.
Description: Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care for weight loss.
Description: Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)
Study: NCT03199638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine vs. Placebo
Description: oral supplementation with either glutamine or placebo twice daily for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short bouts of exercise ('exercise snacks') 3 times daily for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short bouts of exercise ('exercise snacks') 3 times daily for 3 months
Study: NCT03751423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Morphine
Description: 10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Fentanyl
Description: 0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketamine
Description: 200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Placebo
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Placebo
Description: This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
Study: NCT03963804

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
Study: NCT04319250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemic compression
Description: ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Program
Description: A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Program
Description: A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
Study: NCT02141165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis, autoCPAP, follow up.
Description: comparison between the efficacy of two protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnosis, autoCPAP, follow up.
Description: comparison between the efficacy of two protocol
Study: NCT02117752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.
Study: NCT03138785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical voriconazole / levofloxacin systemic itraconazole
Description: starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical voriconazole / levofloxacin systemic itraconazole
Description: starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CXL
Description: 30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
Study: NCT01684839

Intervention type: DEVICE
Group type: OTHER
Intervention: Pedicled nerve flap
Description: This nerve flap is a vascularized nerve graft